

# Ping An (2318 HK)

## Robust 3Q doubled in NBV and earnings growth

Ping An recorded robust 3Q earnings with Group net profit and L&H NBV doubled in third quarter. Group OPAT attributable to shareholders grew 5.5% YoY to RMB 113.8bn, translating into a 22.1% YoY increase in 3Q24 on track for a steady recovery (1Q24: -3.0%/2Q24: +1.9% YoY). L&H and P&C accelerated attributable OPAT growth to 8%/455% YoY in 3Q, driven in part by more promising investment results and improved underwriting structure. Group attributable NPAT rose 36.1% YoY in 9M24, implying a surge of 1.51x YoY in 3Q24. L&H NBV rose 34.1% YoY to RMB35.2bn, more than doubled in 3Q24, thanks to excessive margin expansion. Entering into 4Q24, as business shows more clarity, we expect Ping An could grow its NBV over 20% in FY24E, and is likely to sustain this momentum into 1Q25, as mgmt. guided on the call that “the channels are prepared for the jumpstart in FY25 as well as exerting effort to close the book this year with a perfect end”. With rebounded investment income and a low base in 4Q23, we believe a better-than-expected 2H24 earnings is attainable. Given that, we revise up the FY24-FY26E EPS forecast by 14%/7%/3% to RMB 7.44/7.57/7.90 ([table](#)), underpinned by a clearer outlook for both solid insurance and investment results. **Maintain BUY, we revise up our price target based on SOTP ([table](#)) to HK\$65.1, implying 1.09x FY24E P/B and 0.73x FY24E P/EV.**

■ **3Q NBV more than doubled; number of life sales agents stabilized.** Ping An L&H achieved a 34.1% YoY rise in NBV to RMB35.2bn in 9M24, implying more-than-doubled growth by 110.2% YoY to RMB12.8bn in 3Q. All channels contributed to NBV rise, of which agency NBV was up 31.6% YoY to RMB28.6bn in 9M24, composing >80% of total NBV. We estimate it almost doubled (+95% YoY) in 3Q24. Bancassurance NBV surged 68.5% YoY primarily driven by margin expansions with a product mix shifting to par product sales since Sep. NBV from community finance jumped 300% YoY thanks to a better 13-month persistency ratio (+6.6pct). NBV margin rose to 25.4%, up 7.3pct like-for-like, and in 3Q, we reckon it increased to 27.7% (*CMBI estimate*), +1.2pct from 2Q24. We attribute this to 1) lower pricing interest rates in Sep and Oct opened up space for margin increase; and 2) a product mix shifting to par product sales. Agency force stabilized in 3Q24 to 362k, +4.3% from year start /+6.5% QoQ. This was in line with our previous projection that the top life insurers' agency scale could stabilize by end-FY24 and/or in 1H25. **We project Ping An L&H to achieve FY24 NBV growth by 23% YoY with a FYP margin at ~26%.**

■ **P&C highlight on OPAT growth w/ an optimized CoR.** Ping An P&C's OPAT surged 4.55x YoY to RMB4.0bn in 3Q24. Combined ratio (CoR) was down 1.5pct to 97.8% in 9M24, given better risk screening and contracted business of high net loss, i.e. guarantee insurance. Driven by increased insurance revenue (+4.5%) and narrowed CoR (-1.5pct), the UW profit in 9M24 was at RMB5.4bn, +2.28x YoY on a low base last year. Auto CoR deteriorated by 0.8pct to 98.2% due to higher cost of debt from a lower RDR under IFRS17 and elevated NAT CAT claims in 3Q24. Looking ahead, we expect that as the impact of guarantee insurance fades, non-auto CoR could further drop to compensate for the rising claims from auto. **We project FY24 CoR to land at 98.3% by year end.**

■ **Expect valuation upside.** The stock is trading at 0.54x FY24 P/EV and 0.81x FY24 P/B, +0.6/+0.2SD above 3-yr historical avg., ranking top among H-share listed Chinese insurers (now at 0.2x-0.6x FY24 P/EV and 0.5x-1.0x FY24 P/B). We see limited downside given the fundamentals turnaround could support a valuation rebound. Looking ahead, we envisage Ping An to benefit from a more certain outlook for sustainable profitability, as 4Q23 was a low base of net loss. Alongside balanced asset allocation and improved liability structure supported by product mix and a Group-wide customer base, we think Ping An is likely to extend its steady growth in NBV and profitability into 4Q24. **We revise up our FY24-26 earnings forecast by 14%/7%/3% to RMB 7.44/7.57/7.90. Maintain BUY and raise TP to HK\$65.1, implying FY24E 1.09x P/B and 0.73x P/EV.**

### BUY (Maintain)

<b>Target Price</b>	<b>HK\$65.10</b>
(Previous TP)	HK\$52.00)
<b>Up/Downside</b>	<b>35.2%</b>
<b>Current Price</b>	<b>HK\$48.15</b>

#### China Insurance

##### Nika MA

(852) 3900 0805

nikama@cmbi.com.hk

#### Stock Data

Mkt Cap (HK\$ mn)	871,871.7
Avg 3 mths t/o (HK\$ mn)	3,114.4
52w High/Low (HK\$)	59.70/29.80
Total Issued Shares (mn)	18107.4

Source: FactSet

#### Shareholding Structure

Charoen Pokphand Group	13.0%
Company Ltd	
UBS Group AG	10.3%


Source: HKEx

#### Share Performance

	Absolute	Relative
1-mth	27.9%	13.9%
3-mth	39.0%	19.6%
6-mth	50.2%	21.0%

Source: FactSet

#### 12-mth Price Performance



Source: FactSet

#### Related reports:

- Ping An (2318 HK) - 2Q NBV stabilized against a high base; expect to see Group OPAT turnaround, Aug. 27, 2024 ([link](#))
- Ping An (2318 HK) - Expect \$3.5bn CB dilutive effect to be short-term, Jul. 17, 2024 ([link](#))
- Ping An (2318 HK) - 1Q24 NBV beat; Life OPAT y/y turned positive, Apr.15, 2024 ([link](#))
- Ping An (2318 HK) - Resilient DPS despite OPAT decline; EV assumptions change cut VNB more than expected, Mar 27, 2024 ([link](#))
- Ping An (2318 HK) - 1H23 NBV beat consensus; interim dividend up 1.1% YoY reinforcing a long-run growth story, Sep 4, 2023 ([link](#))

### Earnings Summary

(YE 31 Dec)	FY22A	FY23A	FY24E	FY25E	FY26E
Net profit (RMB mn)	134,817	109,274	159,710	161,138	166,893
EPS (Reported)(RMB)	8.78	4.84	7.44	7.57	7.90
Consensus EPS (RMB)	n.a	n.a	7.45	7.56	8.14
P/B (x)	0.9	0.9	0.8	0.7	0.7
P/Embedded value (x)	0.6	0.6	0.5	0.5	0.5
Dividend yield (%)	5.4	5.6	6.0	6.5	7.1
ROE (%)	18.2	9.7	13.9	12.9	12.4

Source: Company data, Bloomberg, CMBIGM estimates

## Changes in key forecasts

(RMB mn)	Current			Previous			Change (% , pct)		
	2024E	2025E	2026E	2024E	2025E	2026E	2024E	2025E	2026E
EPS	7.44	7.57	7.90	6.53	7.05	7.66	14.0%	7.4%	3.0%
Operating EPS	8.16	8.36	8.71	7.01	7.40	7.99	16.5%	12.9%	9.0%
Group NPAT	131,498	133,763	139,617	115,350	124,552	135,487	14.0%	7.4%	3.0%
NBV	37,478	42,126	47,209	34,770	39,064	44,210	7.8%	7.8%	6.8%
NBV margin (FYP basis)	25.7%	26.9%	28.2%	24.1%	26.3%	27.9%	1.6pct	0.7pct	0.3pct
EV	1,471,613	1,537,027	1,606,640	1,436,588	1,491,101	1,551,502	2.4%	3.1%	3.6%
ROE	13.9%	12.9%	12.4%	12.3%	12.3%	12.3%	1.6pct	0.6pct	0.1pct

Source: Company data, CMBIGM estimates

## Rerating rationale

We raise the company's FY24-26E earnings forecasts by 14%/7%/3%, with EPS to grow to RMB 7.44/7.57/7.90 (vs previous: RMB 6.53/7.05/7.66, as stated in our last report ([link](#))). We think the third-quarter earnings confirmed a more certain outlook for the company's full-year profitability, both in terms of OPAT and NPAT. Driven by mark-to-market increases from FVTPL assets, incl. both debt-related, i.e. bonds, and equity-related, i.e. stocks and equity funds, under the stock rally boosted by a blitz of policy stimuli by end Sep, we believe the 3Q figures could be indicative of a solid investment performance in 2H/FY24, and thus enhance the insurer's profitability, book value and embedded value accordingly. We revise up our assumptions on 2H equity gains, which was primarily reflected in the EPS upswing. Given the CSI 300 and SSE Composite index were down 7%/4% in 4Q23, we expect fourth-quarter equity investment gains to presumably perform better compared to the low bases.

By 9M24, Ping An achieved comprehensive investment yield (CIY) at 5%, +1.2pct YoY, implying a positive investment experience variance (IEV) that could add up to the Group embedded value (EV). We estimate the EV investment experience variances could turn positive by FY24, if taken CIY as the benchmark to compare with the actuarial assumption of long-term investment return at 4.5%. This IEV account has been in negatives since 2020.

We adopt sum-of-the part valuation for Ping An Group, with Ping An L&H taken into account by P/EV-RoEV based on Gordon Growth and Ping An P&C as well as AM and Technology segments using the P/B-ROE. With unchanged 12.5% cost of equity, 2% risk free, and 2% terminal growth considering the Group's matured business operation, we assign three core business lines with target multiples as 1) 1.19x target P/EV(x) for Ping An L&H, 2) 0.72x a target P/B for Ping An P&C, and 3) 0.9x target P/B for Ping An Bank, as shown in the [table](#).

For NBV, we expect margin expansions to be the key growth driver, which we assume will rise to ~26% by end FY24, lifting L&H NBV by 8%/8%/7% in FY24-26E, based on our model. Group EV was up 2-4% driven in part by 1) potentially IEV turning positive; 2) better-than-expected NBV prints; and 3) reduced operating experience variances (OEV), if any, given the Group's continuous streamlining in structure and business operations.

## Valuation based on SOTP

No. of shares outstanding (mn)	18,107*
USD/HKD	7.80
CNY/HKD	1.09
Stock price, 21/10/2024	49.05
Upside (%)	24.4%
Prev. target price (HK\$)	52.00
Target price chg. (%)	17.3%
COE	12.5%
Terminal growth (%)	2.0%

Note: we assume FY24 total number of shares outstanding after the company's share buybacks.

(RMB bn, %)	Forward BV/EV	Ownership	Valuation
<b>Life insurance:</b>			
FY24 L&H Embedded value	921.1	99.51%	
Adjusted L&H Embedded value	584.9		
3-yr avg. RoEV	14.6%		
Target P/EV (x)	<b>1.19x</b>		
<b>Target valuation</b>			<b>618.3</b>
<b>P&amp;C insurance:</b>			
FY24 shareholders' equity	134.1	99.55%	
P&C ROE (3-yr avg.)	9.5%		
Target P/B (x)	0.72x		
Underwriting cycle discount			
<b>Target valuation</b>			<b>95.5</b>
<b>Banking</b>			
FY24 shareholders' equity	267.6	57.96%	
PAB ROE	11.5%		
Target P/B (x)	0.90x		
<b>Target valuation</b>			<b>139.6</b>
<b>Securities, Trust, and Others AMC</b>			
FY24 shareholders' equity	247.7	100.00%	
Target P/B (x)	1.00x		
<b>Target valuation</b>			<b>247.7</b>
<b>Sum-of-the-parts valuation</b>			<b>1,177</b>
Conglomerate discount			-10.0%
Target valuation (RMB bn)			<b>1,059</b>
<b>Target price for Financial business (HK\$)</b>			<b>63.9</b>
<b>Target price for Tech business (HK\$)</b>			<b>1.22</b>
<b>Ping An Group Target price (HK\$)</b>			<b>65.1</b>
Implied FY24 P/B (x)			1.09x
Implied FY24 P/EV (x)			0.73x
Implied FY24 P/E (x)			8.01x

Source: Company data, CMBIGM estimates

## Ping An (2318 HK) - 9M24/3Q24 Key metrics

(RMB mn, %)	9M24	9M23	Y/Y %	3Q24	3Q23	Y/Y %	2Q24	2Q23	Y/Y %
<b>OPAT attribute to shareholders:</b>	<b>113,818</b>	<b>107,881</b>	<b>5.5%</b>	<b>35,336</b>	<b>28,931</b>	<b>22.1%</b>	<b>39,774</b>	<b>39,030</b>	<b>1.9%</b>
Life & Health insurance	82,701	80,310	3.0%	28,044	26,023	7.8%	27,369	27,592	-0.8%
P&C insurance	13,923	9,965	39.7%	4,014	723	455.2%	6,035	4,719	27.9%
Bank	23,027	22,972	0.2%	8,028	8,258	-2.8%	6,345	6,252	1.5%
AMC	(2,316)	(4,344)	-46.7%	(3,612)	(5,756)	-37.2%	386	107	260.7%
Technology	369	2,263	-83.7%	78	528	-85.2%	493	1,042	-52.7%
Others	(3,886)	(3,285)	18.3%	(1,216)	(844)	44.1%	(854)	(682)	25.2%
<b>Core 3 business lines (L&amp;H, P&amp;C, PAB)</b>	<b>119,651</b>	<b>113,247</b>	<b>5.7%</b>	<b>40,086</b>	<b>35,004</b>	<b>14.5%</b>	<b>39,749</b>	<b>38,563</b>	<b>3.1%</b>
<b>OPAT mix by business lines (%):</b>									
Life & Health insurance	72.7%	74.4%	-1.8 pct	79.4%	95.5%	-16.1 pct	68.8%	139.1%	-70.3 pct
P&C insurance	12.2%	9.2%	3.0 pct	11.4%	2.5%	8.9 pct	15.2%	12.1%	3.1 pct
Bank	20.2%	21.3%	-1.1 pct	22.7%	28.5%	-5.8 pct	16.0%	16.0%	-0.1 pct
<b>NPAT attribute to shareholders:</b>	<b>119,182</b>	<b>87,575</b>	<b>36.1%</b>	<b>44,563</b>	<b>17,734</b>	<b>151.3%</b>	<b>37,910</b>	<b>31,489</b>	<b>20.4%</b>
Life & Health insurance	80,931	59,953	35.0%	30,319	14,832	104.4%	25,466	20,150	26.4%
P&C insurance	13,923	9,965	39.7%	4,014	723	455.2%	6,035	4,719	27.9%
Bank	23,027	22,972	0.2%	8,028	8,258	-2.8%	6,345	6,252	1.5%
AMC	(2,316)	(4,344)	-46.7%	(3,612)	(5,756)	-37.2%	386	107	260.7%
Technology	13,305	2,314	475.0%	12,832	521	2363.0%	532	943	-43.6%
Others	(9,688)	(3,285)	194.9%	(7,018)	(844)	731.5%	(854)	(682)	25.2%
<b>Core 3 business lines (L&amp;H, P&amp;C, PAB)</b>	<b>117,881</b>	<b>92,890</b>	<b>26.9%</b>	<b>42,361</b>	<b>23,813</b>	<b>77.9%</b>	<b>37,846</b>	<b>31,121</b>	<b>21.6%</b>
	9M24	2023	Y/Y %	1H24	2023	Y/Y %	1Q24	2023	Y/Y %
Net asset value attribute to shareholders:	907,939	899,011	1.0%	931,208	899,011	3.6%	904,970	899,011	0.7%

Source: Company data, CMBIGM

Ping An Life & Health	9M24	9M23	Y/Y %	3Q24	3Q23	Y/Y %	2Q24	2Q23	Y/Y %
NBV	35,160	26,219	34.1%	12,840	6,107	110.2%	9,430	9,433	0.0%
NBV margin (%)	25.4	18.1	7.3 pct	27.7	19.8	7.9 pct	26.5	19.5	7.0 pct
<b>Solvency ratios (%):</b>	<b>3Q24</b>	<b>2Q24</b>	<b>Q/Q %</b>	<b>2Q24</b>	<b>1Q24</b>	<b>Q/Q %</b>	<b>1Q24</b>	<b>4Q23</b>	<b>Q/Q %</b>
Life core solvency (%)	119.4	123.6	-4.2 pct	123.6	118.8	4.8 pct	118.8	105.0	13.8 pct
Life comprehensive solvency (%)	200.5	208.8	-8.3 pct	208.8	206.0	2.8 pct	206.0	194.7	11.3 pct
<b>Premiums breakdown:</b>	<b>9M24</b>	<b>9M23</b>	<b>Y/Y %</b>	<b>3Q24</b>	<b>3Q23</b>	<b>Y/Y %</b>	<b>2Q24</b>	<b>2Q23</b>	<b>Y/Y %</b>
First-year premiums (FYP)	138,624	144,764	-4.2%	46,406	30,863	50.4%	35,590	48,387	-26.4%
Written premiums	527,245	497,538	6.0%	139,479	117,620	18.6%	149,620	145,585	2.8%
Life premium income	449,804	409,703	9.8%	128,932	103,991	24.0%	135,526	122,511	10.6%
<b>Agency scale:</b>	<b>3Q24</b>	<b>2Q24</b>	<b>Q/Q %</b>	<b>2Q24</b>	<b>1Q24</b>	<b>Q/Q %</b>	<b>1Q24</b>	<b>4Q23</b>	<b>Q/Q %</b>
No. of life sales agents(mn)	0.36	0.34	6.5%	0.34	0.40	-15.8%	0.40	0.45	-9.2%
<b>Agency productivity:</b>	<b>1Q24</b>	<b>1H24</b>	<b>9M24</b>						
Agent productivity (VNB per agent), YoY%	56.4%	36.0%	54.7%						

Source: Company data, CMBIGM

Ping An P&C	9M24	9M23	Y/Y %	3Q24	3Q23	Y/Y %	2Q24	2Q23	Y/Y %
<b>P&amp;C underwriting combined ratio (%):</b>	<b>97.8</b>	<b>99.3</b>	<b>-1.5 pct</b>						
Auto CoR	98.2	97.4	<b>0.8 pct</b>						
<b>P&amp;C premium income by product:</b>									
Auto	160,535	154,661	3.8%	55,711	53,313	4.5%	53,026	51,323	3.3%
Non-auto, excl. A&H	55,242	53,360	3.5%	15,525	12,720	22.1%	21,529	20,488	5.1%
A&H	23,594	17,911	<b>31.8%</b>	7,738	5,763	<b>34.3%</b>	6,766	5,367	<b>26.1%</b>
<b>Total P&amp;C Premium Income</b>	<b>239,371</b>	<b>225,932</b>	<b>5.9%</b>	<b>78,974</b>	<b>71,796</b>	<b>10.0%</b>	<b>81,321</b>	<b>77,178</b>	<b>5.4%</b>
<b>CROSS-II Solvency ratios (%):</b>									
	<b>3Q24</b>	<b>2Q24</b>	<b>Q/Q %</b>	<b>2Q23</b>	<b>1Q23</b>	<b>Q/Q %</b>	<b>1Q23</b>	<b>4Q22</b>	<b>Q/Q %</b>
<b>P&amp;C core solvency ratio (%)</b>	<b>176.3</b>	<b>181.9</b>	<b>-5.6 pct</b>	<b>181.9</b>	<b>173.8</b>	<b>8.1 pct</b>	<b>173.8</b>	<b>169.4</b>	<b>4.4 pct</b>
P&C comprehensive solvency ratio (%)	215.4	205.0	10.4 pct	205.0	199.1	5.9 pct	199.1	207.8	-8.7 pct

Source: Company data, CMBIGM

Ping An Bank	9M24	9M23	Y/Y %
<b>Net interest margin (NIM)</b>	<b>1.93</b>	<b>2.47</b>	<b>-0.54 pct</b>
Cost-to-Income ratio	27.40	26.55	0.85 pct
Non-performing loan ratio (NPL ratio %)	1.06	1.04	0.02 pct
<b>Provision coverage ratio %</b>	<b>251.19</b>	<b>282.62</b>	<b>-31.43 pct</b>
<b>Capital adequacy %:</b>			
Core T1	<b>9.33</b>	<b>9.23</b>	<b>0.10 pct</b>
T1	10.93	10.95	-0.02 pct
Capital adequacy ratio	13.39	13.52	-0.13 pct

Source: Company data, CMBIGM

Investment performance:	9M24	9M23	Y/Y %
<b>Net investment yield (%), annualized</b>	<b>3.8</b>	<b>4.0</b>	<b>-0.2 pct</b>
<b>Comprehensive yield (%), annualized</b>	<b>5.0</b>	<b>3.7</b>	<b>1.3 pct</b>
<b>B/S investment items:</b>			
	<b>9M24</b>	<b>2023</b>	<b>Chg.</b>
<b>Total investment assets (RMB mn)</b>	<b>5,321,951</b>	<b>4,722,228</b>	<b>12.7%</b>
Non-standard debt (NSA debt)	376,174	416,810	-9.7%
Real estate investments	205,026	203,987	0.5%
<b>Total investment asset mix by types (%)</b>			
NSA debt investments %	7.1%	8.8%	-1.8 pct
Real estate investments %	3.9%	4.3%	-0.5 pct
<b>Among real estate investments:</b>			
real properties %	80.6%	78.4%	2.2 pct
equity-type %	4.4%	4.3%	0.1 pct
debt-type %	15.0%	17.3%	-2.3 pct

Source: Company data, CMBIGM

## Financial Summary

INCOME STATEMENT	2021A	2022A	2023A	2024E	2025E	2026E
<b>YE 31 Dec (RMB mn)</b>						
<b>Insurance revenue</b>		<b>525,981</b>	<b>536,440</b>	<b>556,227</b>	<b>606,998</b>	<b>671,384</b>
<b>Insurance service expenses</b>		<b>(422,221)</b>	<b>(440,178)</b>	<b>(456,718)</b>	<b>(502,598)</b>	<b>(561,652)</b>
Net expenses from reinsurance contracts held		(4,314)	(3,731)	(4,025)	(4,637)	(5,364)
<b>Insurance service results</b>		<b>99,368</b>	<b>92,301</b>	<b>95,138</b>	<b>99,555</b>	<b>104,129</b>
Net finance (expenses)/income from insurance contracts		(99,933)	(123,959)	(125,323)	(124,609)	(134,821)
Net finance (expenses)/income from reinsurance contracts		564	542	477	0	0
Interest income		115,933	118,503	181,334	165,063	172,800
Net investment income		(2,311)	33,324	52,094	59,697	64,691
Other gains/(losses) from changes in fair value		(17,752)	(16,238)	(9,884)	(11,291)	(13,117)
<b>Net investment results</b>		<b>(3,499)</b>	<b>12,172</b>	<b>98,698</b>	<b>88,861</b>	<b>89,552</b>
Net interest income from banking operations		131,096	118,947	108,871	118,295	119,650
Net interest income/(expenses) from non-banking operations		(22,698)	(24,346)	(21,477)	(20,591)	(22,221)
Loan loss provisions		(64,168)	(62,833)	(61,376)	(65,122)	(65,359)
Other fee and commission income/(expenses)		(9,928)	(8,773)	(7,328)	(7,503)	(7,575)
Other income		60,652	68,804	63,271	74,274	87,290
Other expenses		(107,779)	(123,515)	(126,506)	(140,283)	(154,656)
Foreign exchange gains/losses		3,144	120	(1,049)	(1,082)	(1,082)
<b>Other results</b>		<b>36,301</b>	<b>14,210</b>	<b>(4,259)</b>	<b>(3,742)</b>	<b>(8,419)</b>
<b>Profit before tax</b>		<b>142,335</b>	<b>120,117</b>	<b>187,701</b>	<b>183,304</b>	<b>184,297</b>
Income taxes		(7,518)	(10,843)	(27,991)	(22,165)	(17,405)
<b>Net profit</b>		<b>134,817</b>	<b>109,274</b>	<b>159,710</b>	<b>161,138</b>	<b>166,893</b>
Net profit attributable to shareholders		111,008	85,665	131,498	133,763	139,617

BALANCE SHEET	2021A	2022A	2023A	2024E	2025E	2026E
<b>YE 31 Dec (RMB mn)</b>						
<b>ASSETS</b>						
Cash and amount due from banks and other financial institutions		774,841	804,077	835,505	879,798	934,920
Balances with central bank and statutory deposits		295,559	285,879	352,943	435,739	537,959
Intangible assets		99,411	99,078	96,245	93,492	90,818
Investments in associates and joint ventures		280,793	258,877	252,124	257,192	262,362
Property		53,657	50,401	49,576	48,765	47,967
Investment property		114,763	121,406	124,957	133,806	144,564
Reinsurance contract assets		20,615	22,215	24,972	27,350	30,061
Loans and advances to customers		3,242,258	3,320,110	3,483,314	3,742,786	4,005,093
Fixed maturity investments		4,729,856	4,976,779	5,529,375	5,937,422	6,432,584
Equity investments		1,073,763	1,130,853	1,147,029	1,228,260	1,327,012
Derivative financial assets		29,278	44,978	52,331	54,445	56,645
Deferred tax assets		89,321	101,337	97,316	93,454	89,746
Other assets		205,825	367,427	704,379	673,559	500,937
<b>Total assets</b>		<b>11,009,940</b>	<b>11,583,417</b>	<b>12,750,066</b>	<b>13,606,068</b>	<b>14,460,668</b>
<b>LIABILITIES</b>						
Due to banks and other financial institutes		923,088	963,718	1,139,718	1,199,145	1,259,103
Customer deposits and payables to brokerage customers		3,431,999	3,534,539	3,745,312	3,970,031	4,130,420
Insurance contract liabilities		3,671,177	4,159,801	4,834,925	5,295,246	5,820,176
Obligations under repurchase agreements		271,737	241,803	268,871	298,969	332,436
Derivative financial instruments		39,738	44,531	44,996	45,900	46,822
Deferred tax liabilities		14,217	14,148	14,361	14,577	14,796
Current tax liabilities		16,076	7,117	4,482	2,823	1,778
Other liabilities		1,455,807	1,388,743	1,369,238	1,350,007	1,331,046
<b>Total liabilities</b>		<b>9,823,944</b>	<b>10,354,453</b>	<b>11,421,903</b>	<b>12,176,698</b>	<b>12,936,577</b>
<b>EQUITIES</b>						
Share capital		18,280	18,210	18,107	18,107	18,107
Reserves		268,724	263,752	267,745	275,338	274,609
Retained profits		593,183	622,050	709,737	795,554	883,026
<b>Total shareholders' equity</b>		<b>869,191</b>	<b>899,011</b>	<b>990,589</b>	<b>1,083,998</b>	<b>1,170,741</b>
Non-controlling interests		316,805	329,953	337,575	345,372	353,350
<b>Total equity</b>		<b>1,185,996</b>	<b>1,228,964</b>	<b>1,328,163</b>	<b>1,429,370</b>	<b>1,524,091</b>
<b>Total liabilities &amp; equity</b>		<b>11,009,940</b>	<b>11,583,417</b>	<b>12,750,066</b>	<b>13,606,068</b>	<b>14,460,668</b>

PER SHARE DATA	2021A	2022A	2023A	2024E	2025E	2026E
<b>YE 31 Dec</b>						
DPS	2.36	2.40	2.48	2.64	2.85	3.13
EPS (Reported)	5.77	8.78	4.84	7.44	7.57	7.90
Consensus EPS	n.a	n.a	n.a	7.45	7.56	8.14
Group embedded value/share (HK\$)	76.34	77.89	76.34	81.27	84.88	88.73
No. of shares basic	18,280	18,280	18,210	18,107	18,107	18,107
PROFITABILITY	2021A	2022A	2023A	2024E	2025E	2026E
<b>YE 31 Dec</b>						
Return on equity (ROE)		18.2%	9.7%	13.9%	12.9%	12.4%
Combined ratio		100.3%	100.7%	98.3%	97.2%	96.7%
VALUATION	2021A	2022A	2023A	2024E	2025E	2026E
<b>YE 31 Dec</b>						
P/Embedded value (x)	0.6	0.6	0.6	0.5	0.5	0.5
P/B (x)	1.0	0.9	0.9	0.8	0.7	0.7
Dividend yield (%)	5.4	5.4	5.6	6.0	6.5	7.1

Source: Company data, CMBIGM estimates. Note: The calculation of net cash includes financial assets. | Note: stock price data by market close on Oct 22, 2024.



# Disclosures & Disclaimers

## Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

## CMBIGM Ratings

**BUY** : Stock with potential return of over 15% over next 12 months  
**HOLD** : Stock with potential return of +15% to -10% over next 12 months  
**SELL** : Stock with potential loss of over 10% over next 12 months  
**NOT RATED** : Stock is not rated by CMBIGM

**OUTPERFORM** : Industry expected to outperform the relevant broad market benchmark over next 12 months  
**MARKET-PERFORM** : Industry expected to perform in-line with the relevant broad market benchmark over next 12 months  
**UNDERPERFORM** : Industry expected to underperform the relevant broad market benchmark over next 12 months

## CMB International Global Markets Limited

**Address:** 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

**CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)**

## Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM.

Additional information on recommended securities is available upon request.

### For recipients of this document in the United Kingdom

This report has been provided only to persons (I) falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.") of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

### For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

### For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.